CS-12192 is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CS-12192’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CS-12192 overview

CS-12192 is under development for the treatment of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, prurigo, alopecia areata, idiopathic dermatitis and graft versus host disease (GVHD). The drug candidate is a new molecular entity, which acts by targeting JAK3, JAK1 and TBK1 enzymes. It is administered through oral route in the form of capsule. 

Shenzhen Chipscreen Biosciences overview

Shenzhen Chipscreen Biosciences (Chipscreen) is a biotechnology company. The company develops drugs in therapeutic areas of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals. Its product pipeline includes Chidamide, Siglitastat sodium, Cioroni, CS12192 and others. Its chidamide product is a novel subtype-selective HDAC inhibitor functioning as an epigenetic modulator for the treatment of various hematological and solid cancers. Chipscreen offers protocol design, clinical research and monitoring, and data analysis and management services. The company provides clinical and preclinical stage programs in various therapeutic areas. It operates in China. Chipscreen is headquartered in Shenzhen, Guangdong, China.

For a complete picture of CS-12192’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.